Zimmer Biomet Exceeds Expectations in Q4 and Forecasts Revenue Growth for FY2023

Trending News ☀️

Zimmer Biomet ($NYSE:ZBH) is a leader in musculoskeletal health technology, with a mission to alleviate pain and improve the quality of life for people around the world. Recently, Zimmer Biomet reported strong fourth quarter and full-year results, exceeding expectations. The company’s Q4 Non-GAAP Earnings Per Share (EPS) of $1.88 beat consensus estimates by $0.05, while revenue of $1.83 billion exceeded expectations by $70 million. This was attributed to an increase in sales of orthopedic implants and sports medicine products. For Fiscal Year 2023, Zimmer Biomet is forecasting revenue growth between 1.5% and 3.5%, compared to the consensus growth rate of 1.9%. This is due to the company’s strong sales performance and focus on innovative technologies.

Additionally, Zimmer Biomet expects Adjusted EPS of $6.95 to $7.15, surpassing the consensus estimate of $6.99. The company’s strong performance and outlook for FY2023 bodes well for investors, as it demonstrates Zimmer Biomet’s commitment to providing quality products and services to its customers. The company’s focus on innovation and technology will continue to drive growth in the coming years and help it to stay ahead of the competition.

Stock Price

The company’s stock opened at $127.6 and closed at $129.4, up by 1.6% from its previous closing price of 127.4. The company also reported strong sales growth in its spinal implant segment, and strong performance in its Orthopedic Reconstructive and Sports Medicine segments. In addition to the strong fourth quarter results, the company also provided guidance for the upcoming fiscal year.

The company’s strong performance in the fourth quarter and its guidance for the upcoming year provide investors with confidence in the direction of the company. With continued strong performance, Zimmer Biomet could be well-positioned for continued success in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Zimmer Biomet. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Zimmer Biomet. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Zimmer Biomet. More…

Key Ratios Snapshot

Some of the financial key ratios for Zimmer Biomet are shown below. More…

Analysis

GoodWhale provides a comprehensive analysis of ZIMMER BIOMET‘s financials and business operations, allowing investors to make informed decisions about investing. According to the Risk Rating, ZIMMER BIOMET is a high risk investment. GoodWhale has identified three risk warnings in the income sheet, balance sheet, and non-financial aspects of the company. The income sheet provides an overview of a company’s financial performance, including revenues and expenses. GoodWhale’s analysis looks at both short and long-term trends that could affect the company’s ability to generate profits. The balance sheet provides an overview of a company’s assets and liabilities, and GoodWhale’s analysis looks for potential risks that could affect the company’s financial health. Finally, the non-financial aspects of a company are also analyzed, including corporate governance and management structure. GoodWhale provides investors with a comprehensive overview of ZIMMER BIOMET’s financials and business operations, which can help investors make informed decisions about investing in the company. By analyzing both financial and non-financial indicators, GoodWhale can help identify potential risks that could affect the company’s long-term success. Investors are encouraged to register with GoodWhale to gain access to detailed analyses of ZIMMER BIOMET’s financials and business operations. More…

Peers

The company operates in two segments, Reconstructive and Dental. It offers knee, hip, shoulder, elbow, hand and wrist, foot and ankle, and biologics products. The company also provides dental prosthetics, including dental implants and CAD/CAM systems; and digital equipment for dentists and laboratories. Zimmer Biomet has a market cap of $24.4 billion and is headquartered in Warsaw, Indiana.

– Alcon Inc ($LTS:0A0D)

Alcon Inc is a global medical company that specializes in eye care products and services. The company’s market cap as of 2022 is 30.09B, and its return on equity is 1.87%. Alcon’s products and services include contact lenses, intraocular lenses, ophthalmic surgical devices, and ophthalmic pharmaceuticals. The company has a presence in over 100 countries and serves customers in the retail, wholesale, and government sectors.

– Sonova Holding AG ($LTS:0QPY)

Sonova Holding AG is a Swiss manufacturer of hearing aids. The company was founded in 1947 and is headquartered in Zurich, Switzerland. As of 2020, Sonova Holding AG had a market cap of 15.37 billion Swiss francs and a return on equity of 18.9%. The company’s products are sold under the brand names Phonak, Unitron, and Advanced Bionics. Sonova Holding AG’s products are available in more than 100 countries.

– Tandem Diabetes Care Inc ($NASDAQ:TNDM)

Tandem Diabetes Care Inc is a medical device company that develops, manufactures and sells insulin pumps for people with diabetes. The company has a market cap of $2.56 billion and a return on equity of -8.79%. Tandem’s products include the t:slim X2 insulin pump, the t:flex insulin pump, and the t:slim G4 insulin pump. The company also offers the t:lock Connectivity System, a cloud-based software platform that allows users to manage their diabetes devices and data.

Summary

Looking ahead, the company is investing in technology, expanding its sales and marketing capabilities, and enhancing its product portfolio to drive future growth. Its strong financial performance indicates that Zimmer Biomet remains well-positioned to continue to succeed in the future.